Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency

Pediatric Transplantation

Volumn 11, Issue 2, 2007, Pages 209-213

  Stankova, Jitka ^a   Carret, Anne Sophie ^a   Moore, Dorothy ^a   McCusker, Christine ^a   Mitchell, David ^a   Davis, Michael ^a   Mazer, Bruce ^a   Jabado, Nada ^a,b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Aerosolized; Parainfluenza 3; Ribavirin; Severe combined immunodeficiency syndrome; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RIBAVIRIN;

AEROSOL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANDIDIASIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMBINED IMMUNODEFICIENCY; COUGHING; DRUG ERUPTION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; MYELOABLATIVE CONDITIONING; PARAINFLUENZA VIRUS 3; PRESCHOOL CHILD; RNA VIRUS INFECTION; SEPSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

AEROSOLS; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; PARAINFLUENZA VIRUS 3, HUMAN; REOPERATION; RESPIROVIRUS INFECTIONS; RIBAVIRIN; SEVERE COMBINED IMMUNODEFICIENCY; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 33846634242     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00607.x     Document Type: Article

References (23)

1. FISCHER A, LE DEIST F, HACEIN- BEY-ABINA S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005: 203: 98-109.
2. BUCKLEY RH. Treatment options for genetically determined immunodeficiency. Lancet 2003: 361: 541-542.
3. FISCHER A, HACEIN-BEY-ABINA S, CAVAZZANA-CALVO M. Gene therapy for immunodeficiency diseases. Semin Hematol 2004: 41: 272-278.
4. ANTOINE C, MULLER S, CANT A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99. Lancet 2003: 361: 553-560.
5. BUCKLEY RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 2004: 5(Suppl. A): S225-S233.
6. CROOKS BN, TAYLOR CE, TURNER AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000: 26: 1097-1102.
7. LUJAN-ZILBERMANN J, BENAIM E, TONG X, SRIVASTAVA DK, PATRICK CC, DEVINCENZO JP. Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis 2001: 33: 962-968.
8. LEWIS VA, CHAMPLIN R, ENGLUND J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996: 23: 1033-1037.
9. TAYLOR CE, OSMAN HK, TURNER AJ, et al. Parainfluenza virus and respiratory syncytial virus infection in infants undergoing bone marrow transplantation for severe combined immunodeficiency. Commun Dis Public Health 1998: 1: 202-203.
10. ENGLUND JA, PIEDRA PA, AHN YM, GILBERT BE, HIATT P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994: 125: 635-641.
11. SHULTS RA, BARON S, DECKER J, DEITCHMAN SD, CONNOR JD. Health care worker exposure to aerosolized ribavirin: Biological and air monitoring. J Occup Environ Med 1996: 38: 257-263.
12. SOLDATOU A, DAVIES EG. Respiratory virus infections in the immunocompromised host. Paediatr Respir Rev 2003: 4: 193-204.
13. WENDT CH, WEISDORF DJ, JORDAN MC, BALFOUR HH Jr, HERTZ MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992: 326: 921-926.
14. SPARRELID E, LJUNGMAN P, EKELOF-ANDSTROM E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997: 19: 905-908.
15. NICHOLS WG, COREY L, GOOLEY T, DAVIS C, BOECKH M. Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001: 98: 573-578.
16. ELIZAGA J, OLAVARRIA E, APPERLEY J, GOLDMAN J, WARD K. Parainfluenza virus 3 infection after stem cell transplant: Relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001: 32: 413-418.
17. LJUNGMAN P. Respiratory virus infections in bone marrow transplant recipients: The European perspective. Am J Med 1997: 102(3A): 44-47.
18. GRACI JD, CAMERON CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006: 16: 37-48.
19. KOCHHAR DM, PENNER JD, KNUDSEN TB. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 1980: 52: 99-112.
20. KILHAM L, FERM VH. Congenital anomalies induced in hamster embryos with ribavirin. Science 1977: 195: 413-414.
21. CHAVES J, HUEN A, BUESO-RAMOS C, SAFDAR A, VADHAN-RAJ S. Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with hodgkin lymphoma. Clin Infect Dis 2006: 42: e72-e75.
22. GELFAND EW, MCCURDY D, RAO CP, MIDDLETON PJ. Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease. Lancet 1983: 2: 732-733.
23. GHOSH S, CHAMPLIN RE, ENGLUND J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000: 25: 751-755.